During this segment, the panelists share their final insights about the future of immunotherapy.
Jeffrey Weber, MD, PhD, believes that treating patients with immunotherapy will benefit all parties involved in healthcare and does not fear the shift toward “Obamacare.” Dr Weber explains that even as treatment decisions become more data driven, he does not believe that much will change in the way that great physicians consider and treat their patients.
Daniel J. George, MD, is equally excited for the future of immunotherapy, although he is concerned that there is currently an educational lag when considering the different factors associated with immunotherapy. However, he does believe that as immunotherapy becomes a more common treatment modality for fields other than oncology, this barrier will be overcome.
Michael Kolodziej, MD, concludes the discussion by explaining that immunotherapy is in its “golden age.” Furthermore, Dr Kolodziej believes that healthcare reform offers the oncology field, pharmaceutical industry, and the entire healthcare enterprise the opportunity to redefine their roles in positive ways.
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More